Category Archives: Press Release

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Anuj Kalsy, Lead, Data & Strategy, and Sr. Director of Pharmaceutical Arrangements at BioReference Health

Elmwood Park, NJ – November 28, 2023 – BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data (“RWD”) for the pharmaceutical and life science industries. This collaborative arrangement will offer healthcare providers and researchers unique solutions […]

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Ellen Beausang Quote

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON, MA, ELMWOOD PARK, NJ, and Rolle, Switzerland, November 7, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that […]

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

Quote: We’re proud to be offering our patients more clarity and information that can empower them to better manage and understand their health

CINtec® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, NJ, February 9, 2023 – BioReference® Health LLC, one of the largest full-service specialty laboratories in the United States, announced today it will be one of the first commercial laboratories to use offer the CINtec® PLUS Cytology test from […]

Aspira Women’s Health Announces Formal Launch of Co-Marketing and Distribution Collaboration with BioReference

Aspira Women’s Health Inc. OVA1Plus® now available to an expanded network of physicians, supporting patients nationwide AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the formal launch of its co-marketing and distribution collaboration with BioReference®, an OPKO Health […]

Cue Health and BioReference Laboratories Bring Point-of-Care Solutions to the Clinical Setting

Cue Health debuts Cue Clinic™ dashboard to give healthcare providers more choice and control over patient care as part of BioReference’s product offering SAN DIEGO and ELMWOOD PARK, N.J., April 5, 2022 /PRNewswire/ — Cue Health Inc. (“Cue”) (Nasdaq: HLTH), the healthcare technology company behind one of the country’s most accurate COVID-19 tests and BioReference Laboratories, Inc., an OPKO Health company (“BioReference”), today announced […]

BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.

ELMWOOD PARK, N.J., November 29, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), announced COVID-19 testing preparedness for the Omicron Variant. BioReference’s PCR diagnostic tests for SARS-CoV-2 COVID-19 are based on recognizing specific RNA target genes that are common to all coronaviruses. To date, the diagnostic targets have not changed with the novel […]

Richard Schwabacher Named to Modern Healthcare’s Top 25 Emerging Leaders List

ELMWOOD PARK, NJ and Chicago, IL (October 6, 2021) – BioReference Laboratories’ Richard Schwabacher is among Modern Healthcare’s 2021 class of Top 25 Emerging Leaders. Modern Healthcare, the leader in healthcare business news, research and data, annually honors emerging leaders all age 40 or under, who have made significant contributions in the areas of innovation […]

Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program

New York students K-12 will have the opportunity for COVID-19 testing prior to or at the start of the 2021-2022 school year through Rite Aid and BioReference CAMP HILL, Pa. (August 26, 2021) – Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health […]

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

ELMWOOD PARK, N.J., August 16, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche. Ariosa’s non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in […]

BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry

MIAMI, June 22, 2021 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers. Under the agreement, unvaccinated guests will be required to undergo rapid, point-of-care PCR COVID-19 prior to embarking. These guests will […]